Corporate Tech Investors

Amgen Ventures

Amgen Ventures is a corporate VC investing group that partners with companies that are a good strategic fit.

Venture Investor Overview

Venture Investor
Amgen Ventures
Status
Active
Investor Type
Corporate
Activity Level
Funds Raised
Industry Focus
Biopharmaceutical
Enterprise IT
Healthcare IT
Medical Devices & Instruments

Contact Information

Contact
Robert Bradway
Title
Chief Executive Officer
Mailing Address
1 Amgen Center Dr.
Thousand Oaks, CA 91320
USA
Email Address

Background Information

Overview
As a company formed with venture capital funding 25 years ago, we understand the challenges faced by early-stage biotechnology companies. In 2004, we announced the formation of Amgen Ventures, our corporate venture capital fund. With an initial investment of $100 million, the fund is designed to provide emerging biotechnology companies with resources to develop pioneering discoveries focused on human therapeutics. Amgen Ventures reflects Amgen's commitment to helping patients through cutting-edge science and our desire to transform science through innovation.
Profile
Amgen Ventures LinkedIn Company Profile
Social Media
Amgen Ventures Company Twitter Account
Company News
Amgen Ventures News
Facebook
Amgen Ventures on Facebook
YouTube
Amgen Ventures on YouTube
Last Transaction
9/4/2024

Transaction History

Our records indicate that Amgen Ventures invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
9/4/2024
Unknown
6/6/2024
Unknown
4/30/2024
$100,000,000
2/13/2024
$170,000,000
12/4/2023
$121,000,000
11/29/2023
$10,000,000
10/10/2023
$34,000,000
9/19/2023
$50,000,000
9/15/2023
$273,000,000
6/13/2023
$16,500,000
3/9/2023
$88,000,000
11/15/2022
$46,000,000
11/8/2022
$5,000,000
10/17/2022
$69,000,000
10/11/2022
$112,000,000
9/20/2022
$14,000,000
7/20/2022
$75,000,000
7/7/2022
$25,000,000
6/29/2022
$120,000,000
6/7/2022
$75,000,000
3/24/2022
Unknown
3/4/2022
$14,000,000
2/5/2022
$40,000,000
9/13/2021
$115,000,000
8/31/2021
$60,000,000
5/27/2021
$160,000,000
1/7/2021
$105,000,000
12/23/2020
$81,000,000
11/20/2020
$80,000,000
10/2/2020
$47,000,000
8/31/2020
$82,000,000
8/21/2020
$40,000,000
6/2/2020
$30,000,000
5/15/2020
$42,000,000
4/3/2020
$25,500,000
2/21/2020
$10,000,000
9/6/2019
$114,000,000
7/10/2019
$23,000,000
4/26/2019
Unknown
3/22/2019
$40,000,000
2/6/2019
$27,000,000
11/27/2018
$23,000,000
11/20/2018
$5,500,000
11/14/2018
$30,000,000
7/30/2018
$85,400,000
7/26/2018
$133,000,000
6/27/2018
$110,000,000
5/10/2018
$55,000,000
4/12/2018
$36,400,000
4/6/2018
Unknown
2/28/2018
$53,000,000
12/7/2017
$49,500,000
11/15/2017
$30,000,000
11/9/2017
$25,000,000
10/31/2017
$30,000,000
4/26/2017
$29,000,000
1/11/2017
$15,000,000
7/20/2016
$11,900,000
3/8/2016
$43,000,000
1/7/2016
$29,500,000
11/10/2015
$41,000,000
7/23/2015
$58,500,000
1/9/2015
$35,000,000
11/11/2014
$33,100,000
11/4/2014
$26,500,000
7/23/2014
$3,000,000
7/1/2014
$7,000,000
1/10/2014
$13,500,000
12/31/2013
$17,999,000
12/18/2013
$38,500,000
12/11/2013
$26,000,000
3/25/2013
$14,000,000
5/16/2012
$8,600,000
4/24/2012
$20,000,000
9/8/2011
$10,600,000
8/31/2011
$30,000,000
6/30/2011
$2,399,900
5/25/2011
$2,100,000
1/5/2011
$23,000,000
12/31/2010
$1,500,200
12/31/2010
$1,999,900
12/31/2010
$5,719,000
11/17/2010
$36,500,000
9/27/2010
$1,000,000
8/11/2010
$32,000,000
6/30/2010
$40,000,000
10/7/2009
$32,000,000
6/30/2009
$2,101,800
6/2/2009
$12,000,000
5/5/2009
$30,000,000
12/31/2008
$4,500,000
9/30/2008
$3,634,000
9/30/2008
$700,000
9/30/2008
$600,000
8/4/2008
$18,250,000
1/3/2008
$5,200,000
12/31/2007
$650,000
12/31/2007
$15,735,000
10/29/2007
$33,000,000
10/26/2007
$30,000,000
8/3/2007
$22,500,000
6/25/2007
$15,800,000
3/31/2007
$2,499,900
3/19/2007
$29,000,000
3/6/2007
$21,000,000
12/31/2006
$1,050,000
9/30/2006
$2,085,000
6/30/2006
$21,000,000
6/16/2006
$55,000,000
6/12/2006
$36,000,000
5/9/2006
$43,800,000
11/10/2005
$26,600,000
9/22/2005
$9,000,000
5/5/2005
$28,500,000
3/31/2005
$10,589,000
3/31/2005
$800,000
11/18/2004
$11,800,000

 


Investor Contacts

Title
Name
Email & Social
Chief Executive Officer
Robert Bradway
  Robert Bradway LinkedIn Profile  Robert Bradway Twitter Account  Robert Bradway News  Robert Bradway on Facebook

 


Funds

No fund closings have been recorded for this company.

 


Portfolio Companies

Amgen Ventures has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company

 

 


 

 

Browse more corporate investors:

Ameritas Holding Company | AMN Healthcare Services

 

Share this article

 


About Our Corporate Tech Investor Database

This corporate tech investor profile is powered by VentureDeal.com, a leading provider of corporate tech investing transaction data.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary